Jing Chen

Title: Innovations in Prostate Cancer Diagnosis by Jing Chen

Introduction

Jing Chen is an accomplished inventor based in Baltimore, MD (US). She has made significant contributions to the field of medical diagnostics, particularly in the area of prostate cancer. Her innovative work focuses on identifying biomarkers that can aid in the diagnosis of aggressive prostate cancer.

Latest Patents

Jing Chen holds a patent for her invention titled "Biomarkers for aggressive prostate cancer." This patent relates to the identification of biomarkers that are useful in diagnosing aggressive forms of prostate cancer. The method involves measuring the levels of specific biomarkers in a patient's sample and comparing these levels to predefined thresholds that indicate the presence or absence of aggressive prostate cancer. The biomarkers identified in her patent include cathepsin-L (CTSL), periostin, microfibrillar-associated protein 4 (MFAP4), collagen XII, neprilysin, clusterin, neutrophil gelatinase associated lipocalin (NGAL), epithelial cell activating molecule (EpCAM), prostate specific antigen (PSA), membrane metallo-endopeptidase (MME), and asporin (ASPN). Jing Chen has 1 patent to her name.

Career Highlights

Jing Chen is affiliated with Johns Hopkins University, where she continues her research and development in the field of biomarkers and cancer diagnostics. Her work has the potential to significantly impact the way aggressive prostate cancer is diagnosed and treated.

Collaborations

Jing Chen has collaborated with notable colleagues, including Hui Zhang and Daniel W. Chan. These collaborations have further enhanced her research and contributed to advancements in the field.

Conclusion

Jing Chen's innovative work in identifying biomarkers for aggressive prostate cancer represents a significant advancement in medical diagnostics. Her contributions are poised to improve patient outcomes and enhance the understanding of prostate cancer.